Interleukin-23 (IL-23)

Interleukin-23 (IL-23) is an inflammatory cytokine that is key for the maintenance and expansion of CD4+ Th17 cells. It is a heterodimeric cytokine composed of an Interleukin-12 subunit beta (IL-12 p40) and an Interleukin 23 (IL-23) subunit alfa.

Monoclonal antibodies such as Guselkumab, Risankizumab, Tildrakizumab, Mirikizumab, and Ustekinumab have been developed to inhibit Interleukin-23 (IL-23) activity in diseases like psoriasis, psoriatic arthritis, and Crohn's disease

Targets for Interleukin-23 (IL-23)

ILC3
Atarashi et al. 2015 Cell 163(2): 367–80
NK cells
Nu et al. 2022 J Immunol 208: 660-671
T helper 17 cell
Miossec et al. 2009 N Engl J Med. 361: 888-898